ARCT

#3520
Arcturus Therapeutics Holdings Inc. Common Stock
8.46 USD
+1.20%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
8.46
8.46
Intervallo Annuale
5.86
24.14
Variazione giornaliera
+1.20%
Variazione Mensile
+24.59%
Variazione di 6 mesi
-55.43%
Variazione Annuale
-14.80%
Chiusura Precedente
8.36
Apertura
8.46
Bid
Ask
Minimo
8.46
High
8.46
Volume
28
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 240.46 M
  • Employee 111
  • Founded 2013
  • CEO Joseph E. Payne
  • Website www.arcturusrx.com
  • Headquarter Delaware, United States
  • FIGI BBG00NNW8JK1
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-2.55
Rapporto prezzo/fatturato
2.05

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.

Notizie